The Bioabsorbables/Bioresorbables Center

Filter Your Results

 

News

 

Pooled 12‐Month Outcomes of BIOSOLVE Studies Reported for Biotronik's Magmaris Resorbable Magnesium Scaffold

August 13, 2018 -- Pooled 12‐month outcomes of BIOSOLVE‐II and BIOSOLVE‐III were published by Michael Haude, MD, et al in Catheterization and Cardiovascular Intervention…

Expanding the Possibilities of PCI

Ted E. Feldman, MD, MSCAI, FACC, FESC

May/June 2018— Now that percutaneous coronary intervention (PCI) has become an established therapeutic option in multiple patient populations, we find ourselves in a position to improve …

Ask the Experts: Will Bioresorbable Scaffolds Ultimately Have a Role?

With Dean J. Kereiakes, MD, FACC, FSCAI; Ron Waksman, MD, FACC, FSCAI, FESC; James B. Hermiller Jr, MD, FACC, MSCAI; and Jarrod D. Frizzell, MD, FACC, SCAI

May/June 2018—Experts discuss the outcomes of the ABSORB trials and what the future may hold for bioresorbable scaffolds.

Two-Year Data Presented From MiStent DESSOLVE III Trial

May 23, 2018 -- Micell Technologies, Inc. announced that a 24-month update on the DESSOLVE III trial of the company's MiStent sirolimus-eluting absorbable-polymer cor…

BIO-RESORT Evaluates Biotronik's Orsiro DES With Ultrathin Bioresorable Polymer

May 24, 2018 -- Biotronik announced that 2-year outcome data from the BIO-RESORT randomized controlled trial were presented by Marlies M. Kok, MD, in a late-breaking clinical …

BIO-RESORT Compares Biodegradable- and Durable-Polymer DESs in Patients at High Bleeding Risk

March 6, 2018 -- In an analysis of the BIO-RESORT randomized trial, very thin-strut biodegradable-polymer drug-eluting stents (BP-DESs) showed similar safety and efficacy as t…

Reva Medical's 2.5-mm Fantom Encore Bioresorbable Scaffold Receives CE Mark Approval

February 26, 2018 -- Reva Medical, Inc. announced European CE Mark approval of the 2.5-mm-diameter size of its Fantom Encore bioresorbable scaffold. The company will begi…

Lepu Medical's NeoVas Bioresorbable Scaffold Shown to Be Noninferior to Metallic Drug-Eluting Stents

February 12, 2018 -- Findings from a randomized controlled trial show that the NeoVas bioresorbable scaffold (BRS; Lepu Medical Technology (Beijing) Co., Ltd.) is noninferior …

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.